AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15206039 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and obese patients
Number of subjects: 45000
Study 15206039 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight patients
Number of subjects: 45000
Study 10732655 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 735
Study 9084574 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg per day for 6 days
Number of subjects: 14
Study 9084574 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 25 mg three times per day for 3 days
Number of subjects: 14
Study 8411613 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 82
Study 8411613 — intervention group
Group type: COMPARATOR
Intervention: Control (no epidural analgesia)
Number of subjects: 82
Study 3490684 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 4 to 6 weeks
Number of subjects: 129
Study 3490684 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole 160/800 mg twice daily for 4 to 6 weeks
Number of subjects: 129
Study 3490684 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 129
Study 3490684 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 129
Study 31233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise capacity measured with the 6-min walk test
Number of subjects: 96
Study 31233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional capacity measured with the Duke Activity Status Index
Number of subjects: 96
Study 31233184 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle function measured with unilateral isotonic heel-lift, bilateral isometric shoulder abduction, and unilateral isotonic shoulder flexion
Number of subjects: 96
Study 29145821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tu Salud ¡Si Cuenta! (TSSC) campaign exposure
Number of subjects: 799
Study 29145821 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to any component of TSSC
Number of subjects: 799
Study 29145821 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to newsletters, CHW discussions, and TV segments
Number of subjects: 799
Study 29145821 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to radio segments
Number of subjects: 799
Study 26008758 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 200
Study 26008758 — intervention group
Group type: COMPARATOR
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 200
Study 23061785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (loading dose 0.25 mg·kg(‐1), infusion 10-20 μg·kg(‐1)·min(‐1))
Number of subjects: 34
Study 23061785 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (loading dose 0.02 mg·kg(‐1), infusion 1-2 μg·kg(‐1)·min(‐1))
Number of subjects: 34
Study 21365212 — intervention group
Group type: EXPERIMENTAL
Intervention: Transseptal sutures
Number of subjects: 200
Study 21365212 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 200
Study 21365212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 18070730 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate tension-free repair (n = 288)
Number of subjects: 353
Study 18070730 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed repair (> 6 months, n = 65)
Number of subjects: 353
Study 18070730 — intervention group
Group type: COMPARATOR
Intervention: Immediate tension-free repair
Number of subjects: 353
Study 18070730 — intervention group
Group type: COMPARATOR
Intervention: Delayed repair
Number of subjects: 353
Study 17058231 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (starting dose of 300 mg orally per day, max 2,400 mg)
Number of subjects: 16
Study 17058231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12629464 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/d)
Number of subjects: 27
Study 12629464 — intervention group
Group type: EXPERIMENTAL
Intervention: HMBCr (3 g/d HMB + 3 g/d Cr)
Number of subjects: 27
Study 12629464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 10392507 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal drainage during total hip arthroplasty
Number of subjects: 40
Study 10392507 — intervention group
Group type: COMPARATOR
Intervention: No drainage during total hip arthroplasty
Number of subjects: 40
Study 8680887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP) 60 mg every 2 weeks
Number of subjects: 140
Study 8680887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP) 120 mg every 4 weeks
Number of subjects: 140
Study 1501418 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Protein Diet (NPD)
Number of subjects: 16
Study 1501418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Protein Diet (LPD)
Number of subjects: 16
Study 6344677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine and heparin (0.5 mg dihydroergotamine plus 5,000 units of heparin administered twice daily)
Number of subjects: 50
Study 6344677 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5,000 units administered three times daily)
Number of subjects: 50
Study 30684635 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus 20-minute mindful breathing
Number of subjects: 63
Study 30684635 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 63
Study 27686971 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib plus erlotinib
Number of subjects: 88
Study 27686971 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 88
Study 27725791 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 82
Study 27725791 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 82
Study 25493677 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (Experimental Group 1)
Number of subjects: 80
Study 25493677 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and 25% glucose (Experimental Group 2)
Number of subjects: 80
Study 25493677 — intervention group
Group type: COMPARATOR
Intervention: 25% glucose (Positive Control Group)
Number of subjects: 80
Study 22682335 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucodepleted buffy-coat platelet pools prepared in additive solution
Number of subjects: 10
Study 20335182 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 5% in oxygen 100% (O(2) group, n=25)
Number of subjects: 50
Study 20335182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 5% in oxygen 40% and nitrous oxide 60% (N(2)O group, n=25)
Number of subjects: 50
Study 20335182 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 5% in oxygen 100% (O(2) group)
Number of subjects: 50
Study 20335182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 5% in oxygen 40% and nitrous oxide 60% (N(2)O group)
Number of subjects: 50
Study 18069511 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% hydrogen peroxide whitening strips used for 30 minutes twice daily for 14 days
Number of subjects: 60
Study 18069511 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide in a custom bleaching tray worn overnight for 14 days
Number of subjects: 60
Study 18069511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (14% hydrogen peroxide and 10% carbamide peroxide)
Number of subjects: 60
Study 16236943 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 72
Study 16236943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintubated group (NPPV)
Number of subjects: 72
Study 16236943 — intervention group
Group type: COMPARATOR
Intervention: Intubated group
Number of subjects: 72
Study 11990445 — intervention group
Group type: COMPARATOR
Intervention: EMD alone
Number of subjects: 16
Study 11990445 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + BDX
Number of subjects: 16
Study 10468703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 24
Study 10468703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 24
Study 10468703 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 10 mg
Number of subjects: 24
Study 10468703 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 24
Study 10468703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (both doses)
Number of subjects: 24
Study 7604669 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional anal manometry
Number of subjects: 40
Study 7604669 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-retaining test
Number of subjects: 40
Study 7604669 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal saline infusion test
Number of subjects: 40
Study 7604669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of routine anal manometry, rectal saline infusion test, and balloon-retaining test
Number of subjects: 40
Study 7604669 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-retaining test vs. rectal saline infusion test
Number of subjects: 40
Study 7604669 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminatory values for maximum basal pressure and squeeze pressure
Number of subjects: 40
Study 1644080 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 12
Study 1644080 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 12
Study 6521482 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-session program targeting cognitive, attitudinal, social, and personality factors related to alcohol misuse.
Number of subjects: 239
Study 31744425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 107
Study 31744425 — intervention group
Group type: COMPARATOR
Intervention: Thrombectomy passes (≥3 passes)
Number of subjects: 107
Study 31744425 — intervention group
Group type: COMPARATOR
Intervention: Baseline NIH Stroke Scale score >17
Number of subjects: 107
Study 29363093 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Initiated Care Consultation (PICC)
Number of subjects: 150
Study 29363093 — intervention group
Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 150
Study 26027619 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 50mg 2x/day for the first 4 weeks followed by 100mg 2x/day for the next 8 weeks
Number of subjects: 0
Study 26027619 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil
Number of subjects: 0
Study 26027619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23104617 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 225
Study 23104617 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus parent training
Number of subjects: 225
Study 23104617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 21744143 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 28
Study 21744143 — intervention group
Group type: COMPARATOR
Intervention: Candesartan or Valsartan (Control)
Number of subjects: 28
Study 18375082 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (mean dose 12.7 mg)
Number of subjects: 151
Study 18375082 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (mean dose 3.9 mg) and Fentanyl (mean dose 108 mcg)
Number of subjects: 151
Study 16776760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertically compacted Epiphany
Number of subjects: 60
Study 16776760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertically compacted gutta‐percha
Number of subjects: 60
Study 16776760 — intervention group
Group type: COMPARATOR
Intervention: Radiographic examination
Number of subjects: 60
Study 16776760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental operating microscope
Number of subjects: 60
Study 14754694 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 266
Study 14754694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 14754694 — intervention group
Group type: COMPARATOR
Intervention: Estrogen-progestin
Number of subjects: 266
Study 11215357 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract H15
Number of subjects: 102
Study 11215357 — intervention group
Group type: COMPARATOR
Intervention: mesalazine
Number of subjects: 102
Study 8931081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia alone (15% O2)
Number of subjects: 27
Study 8931081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia plus 0.5% CO2
Number of subjects: 27
Study 8931081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia plus 2% CO2
Number of subjects: 27
Study 1424420 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg every 4 hours while awake) and naproxen (500 mg every 12 hours for 4 days)
Number of subjects: 12
Study 1424420 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone (200 mg every 4 hours while awake)
Number of subjects: 12
Study 2869950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic agonists
Number of subjects: 0
Study 2869950 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic antagonists
Number of subjects: 0
Study 2869950 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0
Study 31526169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g aminocaproic acid in 200 mL saline
Number of subjects: 70
Study 31526169 — intervention group
Group type: COMPARATOR
Intervention: 200 mL normal saline
Number of subjects: 70
Study 29927791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative femoral fracture reduction device (IFFRD)
Number of subjects: 141
Study 29927791 — intervention group
Group type: COMPARATOR
Intervention: Traction table (TT)
Number of subjects: 141
Study 25940585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed appliances (FA)
Number of subjects: 62
Study 25940585 — intervention group
Group type: COMPARATOR
Intervention: Removable appliances (RA)
Number of subjects: 62
Study 24165958 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (90mg) before exercise
Number of subjects: 10
Study 24165958 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (90mg) before and immediately after exercise
Number of subjects: 10
Study 24165958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 24165958 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (single and double)
Number of subjects: 10
Study 22924332 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economic constructs including impulsivity and RRVfood
Number of subjects: 241
Study 22924332 — intervention group
Group type: EXPERIMENTAL
Intervention: High environmental enrichment
Number of subjects: 241
Study 22924332 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary discounting rate
Number of subjects: 241
Study 20571249 — intervention group
Group type: EXPERIMENTAL
Intervention: pre-treatment with tissue-type plasminogen activator (t-PA) combined with back-up of facilitated PCI
Number of subjects: 101
Study 20571249 — intervention group
Group type: COMPARATOR
Intervention: primary percutaneous coronary intervention (primary PCI)
Number of subjects: 101
Study 20571249 — intervention group
Group type: EXPERIMENTAL
Intervention: facilitated PCI
Number of subjects: 101
Study 20571249 — intervention group
Group type: EXPERIMENTAL
Intervention: prior-t-PA alone
Number of subjects: 101
Study 20571249 — intervention group
Group type: COMPARATOR
Intervention: primary PCI
Number of subjects: 101
Study 17962707 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-flavor sports drink
Number of subjects: 8
Study 17962707 — intervention group
Group type: COMPARATOR
Intervention: Alternate-flavor sports drink (AFSD)
Number of subjects: 8
Study 17962707 — intervention group
Group type: COMPARATOR
Intervention: Cola
Number of subjects: 8
Study 15618381 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiography and MR imaging
Number of subjects: 197
Study 15618381 — intervention group
Group type: COMPARATOR
Intervention: Radiography only
Number of subjects: 197
Study 15618381 — intervention group
Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 197
Study 15618381 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative MR imaging results
Number of subjects: 197
Study 12386574 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning protocol (Group I - 24 patients)
Number of subjects: 49
Study 12386574 — intervention group
Group type: COMPARATOR
Intervention: Conservative weaning (Group II - 25 patients)
Number of subjects: 49
Study 10098782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid-fermented cereal gruel togwa, consumed once a day for 13 consecutive days.
Number of subjects: 0
Study 10098782 — intervention group
Group type: COMPARATOR
Intervention: Unfermented cereal gruel uji (control diet), consumed once a day for 13 consecutive days.
Number of subjects: 0
Study 8636522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal, humidified, O2‐mixture insufflation (TGI) at 3 l/min
Number of subjects: 12
Study 8636522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal, humidified, O2‐mixture insufflation (TGI) at 6 l/min
Number of subjects: 12
Study 8636522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal, humidified, O2‐mixture insufflation (TGI) in distal catheter position
Number of subjects: 12
Study 8636522 — intervention group
Group type: COMPARATOR
Intervention: Intratracheal, humidified, O2‐mixture insufflation (TGI) in proximal catheter position for group 2
Number of subjects: 12
Study 8636522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal, humidified, O2‐mixture insufflation (TGI) in distal catheter position for group 2
Number of subjects: 12
Study 2192529 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication for 3 months
Number of subjects: 10
Study 353597 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 23
Study 353597 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 30711969 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D visualization system
Number of subjects: 61
Study 30711969 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic procedure (control group)
Number of subjects: 61
Study 27901186 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM-OJ (high-fat meal with orange juice)
Number of subjects: 36
Study 27901186 — intervention group
Group type: COMPARATOR
Intervention: HFM-W (high-fat meal with water)
Number of subjects: 36
Study 27901186 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM-OJ
Number of subjects: 36
Study 27901186 — intervention group
Group type: COMPARATOR
Intervention: HFM-OJ vs HFM-W
Number of subjects: 36
Study 26066385 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial injection of local anesthetic (Gp SF)
Number of subjects: 32
Study 26066385 — intervention group
Group type: COMPARATOR
Intervention: Extrafascial injection of local anesthetic (Gp EF)
Number of subjects: 32
Study 23954409 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gum
Number of subjects: 60
Study 23954409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard gum
Number of subjects: 60
Study 23954409 — intervention group
Group type: COMPARATOR
Intervention: Chewing nothing (Control)
Number of subjects: 60
Study 23954409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing (both soft and hard gum)
Number of subjects: 60
Study 20579851 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-rich meal
Number of subjects: 41
Study 20579851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich meal
Number of subjects: 41
Study 20579851 — intervention group
Group type: COMPARATOR
Intervention: Both meals
Number of subjects: 41
Study 20031771 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of the main branch (MB, Taxus‐stent, paclitaxel‐eluting stents) and mandatory side branch (SB) PCI (kissing balloons) with provisional SB stenting (therapy A)
Number of subjects: 110
Study 20031771 — intervention group
Group type: COMPARATOR
Intervention: Stenting of the MB (paclitaxel‐eluting stents) with provisional SB-PCI only when SB had TIMI flow <2 (therapy B)
Number of subjects: 110
Study 20031771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 110
Study 18036082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin 2 mg (PR-melatonin)
Number of subjects: 170
Study 18036082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 15560843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group training protocol combining exercise therapy with principles of behavioural therapy and back school
Number of subjects: 0
Study 15560843 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy guideline care according to the Low Back Pain Guidelines of the Royal Dutch College for Physiotherapy
Number of subjects: 0
Study 11552873 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental program
Number of subjects: 84
Study 11552873 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 11552873 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative group (low-risk preterm infants)
Number of subjects: 84
Study 9577234 — intervention group
Group type: EXPERIMENTAL
Intervention: High OCB
Number of subjects: 284
Study 9577234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low OCB
Number of subjects: 284
Study 9577234 — intervention group
Group type: EXPERIMENTAL
Intervention: Field study (managers' ratings)
Number of subjects: 284
Study 9577234 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory study (students' ratings)
Number of subjects: 284
Study 8147512 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter for intercostal pressure measurement
Number of subjects: 20
Study 8147512 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter for pleural pressure measurement
Number of subjects: 20
Study 3145064 — intervention group
Group type: COMPARATOR
Intervention: 125I labelled soluble human insulin (0.05 U/kg)
Number of subjects: 7